Abstract: The invention relates to a method for preparing microgel particles according to a method of controlled radical polymerization in an aqueous dispersion using particular control agents of the nitroxide type. Use in the biomedical field, and in the field of agrochemistry, cosmetics, surface coatings.
Type:
Application
Filed:
January 28, 2008
Publication date:
June 3, 2010
Applicants:
Arkema France, Centre National De La Recerche Scientifique (CNRS), University of Paris VI
Inventors:
Stephanie Magnet, Bemadette Charleux, Guillaume Delaittre, Maud Save
Abstract: The invention provides an agonist or antagonist of the GPR54 receptor for its use for treating a gonadotropin related disorder, a ligand of the GPR54 receptor for its use for diagnosing a subject's gonadotropin abnormality; a method for screening a compound that affect the gonadotropic axis comprising the step of assaying the compound in the presence of a GPR54 receptor and novel proteins useful in the above.
Type:
Application
Filed:
April 2, 2004
Publication date:
January 25, 2007
Applicants:
INSTITU NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, UNIVERSITY RENE DESCARTES PARIS V, UNIVERSITY PARIS-SUD XI
Inventors:
Nicolas De Roux, Emmanuelle Genin, Edwin Milgrom, Jean-Louis Chaussain, Jean-Claude Carel
Abstract: An isolated DNA encoding the enzyme I-SceI is provided. The DNA sequence can be incorporated in cloning and expression vectors, transformed cell lines and transgenic animals. The vectors are useful in gene mapping and site-directed insertion of genes.
Type:
Grant
Filed:
April 18, 2001
Date of Patent:
August 26, 2003
Assignees:
Institut Pasteur, University Paris VI
Inventors:
Bernard Dujon, Andre Choulika, Laurence Colleaux, Cecile Fairhead, Arnaud Perrin, Anne Plessis, Agnes Thierry
Abstract: An isolated DNA encoding the enzyme I-SceI is provided. The DNA sequence can be incorporated in cloning and expression vectors, transformed cell lines and transgenic animals. The vectors are useful in gene mapping and site-directed insertion of genes.
Type:
Grant
Filed:
November 20, 1998
Date of Patent:
May 29, 2001
Assignees:
Institut Pasteur, University Paris-VI
Inventors:
Bernard Dujon, Andre Choulika, Laurence Colleaux, Cecile Fairhead, Arnaud Perrin, Anne Plessis, Agnes Thierry
Abstract: The present invention provides a biodegradable polymeric stent having a programmed pattern of in vivo degradation. When deployed, the stent comprises a substantially cylindrical element having two open ends and a plurality of regions circumferentially spaced around the cylindrical element and extending from one open end to the other open end of the cylindrical element. Each of the regions is configured to have a desired in vivo lifetime. One region is designed to have a shorter in vivo lifetime than the other region or regions so that when the stent is deployed within the lumen of a vessel of a patient, the cylindrical element breaks apart from one open end of the cylindrical element to the other open end of the cylindrical element within a predetermined period of time after the stent is deployed in the patient. In one preferred embodiment the stent is a formed from a biodegradable polymeric band. The band includes a head having a slot and a tongue having a catch mechanism.
Type:
Grant
Filed:
December 15, 1997
Date of Patent:
September 28, 1999
Assignees:
The Cleveland Clinic Foundation, The University Paris V, Faculte Necker, The Centre National de la Recherche Scientifique, The University of Montpellier I
Inventors:
Antoine Lafont, Michel R. Vert, Fredrick Cornhill, Suming Li, Henri L. Garreau
Abstract: Nucleic acid fragments derived from the HHV6 virus genome, vectors containing said fragments, and their use in the diagnosis of infections involving this virus.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
December 16, 1997
Assignees:
Institute Pasteur, University Paris-VI
Inventors:
Helene Collandre, Luc Montagnier, Henri Agut, Jean-Marie Bechet
Abstract: The present invention is directed to a method for regulating formation of a complex of a plasminogen activator, its receptor and one of its inhibitors. More specifically, this method involves contacting a target cell having a plasminogen activator receptor with a compound which interacts with a component of the complex such that a change in target cell cytoskeletal stiffness results.
Type:
Grant
Filed:
September 28, 1993
Date of Patent:
July 2, 1996
Assignees:
President and Fellows of Harvard University, University of Paris
Inventors:
Ning Wang, Georgia Barlovatz-Meimon, Jeffrey J. Fredberg